Paul gets triple-A rating on royalties fund

New York-based Paul Capital Partners has securitised most of the assets in a $300m drug-royalty fund.

PRIVATE CREDIT

Register to unlock this content

• Daily global private credit news and market intelligence
• Expertly curated insights that keep you ahead of the market
• Faster, data-driven decision making powered by our AI interface, 'Ask PEI'
• Access to proprietary research and reports
• Selected fund performance and investor activity data

Register nowFind out more

DealsFund ManagersPeopleFund Management